Table 3. Change over time in secondary and metabolic outcome measures, by treatment group.
Parameter estimates for the interaction between treatment and time are shown (95% confidence intervals in parentheses) for BMI= body mass index; FVC: functional vital capacity percent of predicted; LDL= low-density lipoprotein; HDL= high-density lipoprotein; hs-CRP= high sensitivity C-reactive protein. Individual pair-wise p-values were calculated from contrasts using fixed effect solutions from models that included all three treatment groups.
| Change over time in Secondary and Metabolic Outcome Measures |
Parameter Estimates (95% CI) | Comparison p-values | ||||
|---|---|---|---|---|---|---|
| Control | HC/HC | HF/HC | Ove rall |
HC/HC vs Cntl |
HF/HC vs Cntl |
|
| Weight (kg/month) | 0•11 (−0•64, 0•86) | 0•39 (−0•16, 0•94) | −0•46 (−1•11, 0•18) | 0•12 | 0•54 | 0•24 |
| BMI (units/month) | −0•04 (−0•34, 0•26) | 0•22 (0•00, 0•44) | −0•17 (0•43, 0•08) | 0•06 | 0•17 | 0•51 |
| ALSFRS-R (units/month) | −2•17 (−3•24, −1•10) | −1•07 (−1•71, −0•42) | −1•54 (−2•36, −0•73) | 0•17 | 0•07 | 0•32 |
| FVC (% predicted/ month) | −3•06 (−6•33, 0•21) | −3•39 (−5•47, −1•31) | −3•84 (−6•40, −1•29) | 0•92 | 0•86 | 0•70 |
| Total Cholesterol (mg/dL/month) | 3•01 (−7•80, 13•81) | 0•45 (−6•65, 7•54) | −4•00 (−12•93, 4•94) | 0•56 | 0•69 | 0•31 |
| LDL Cholesterol (mg/dL/month) | 0•80 (−6•97, 8•57) | −1•90 (−6•81, 3•02) | −8•19 (−14•46, −1•93) | 0•16 | 0•55 | 0•08 |
| HDL Cholesterol (mg/dL/month) | 0•63 (−3•66, 4•92) | −0•58 (−3•65, 2•48) | −1•65 (−5•37, 2•07) | 0•71 | 0•64 | 0•41 |
| Insulin (uU/mL) | 1•50 (0•23, 2•77) | −0•14 (−0•98, 0•71) | −0•13 (−1•16, 0•90) | 0•06 | 0•025 | 0•04 |
| Pre-albumin (mg/dL/month) | −0•22 (−2•72, 2•28) | 0•07 (−1•28, 1•42) | −0•03 (−1•58, 1•51) | 0•98 | 0•83 | 0•89 |
| hs-CRP (mg/L/month) | 0•51 (−0•93, 1•96) | 0•20 (−0•71, 1•10) | 0•33 (−0•79, 1•45) | 0•92 | 0•69 | 0•83 |